VMAT2 Inhibitors Market Size & Share 2025 – 2034

VMAT2 Inhibitors Market Size

The global vesicular monoamine transporter 2 (VMAT2) inhibitors market size was valued at USD 5 billion in 2024. The market is expected to grow from USD 5.4 billion in 2025 to USD 12.3 billion in 2034, at a CAGR of 9.6% during the forecast period. The growth is majorly driven by the increasing prevalence of movement disorders such as Tardive Dyskinesia (TD) and Huntington’s Disease (HD) which necessitate VMAT2 inhibitors such as valbenazine, deutetrabenazine, and tetrabenazine.

For instance, as per Rare Disease Advisor, the prevalence of HD is estimated at 6.37 per 100,000 individuals in Europe and 8.87 per 100,000 in North America, highlighting significant patient populations which drive the demand for effective treatment options such as VMAT2 inhibitor drugs.
 

The emergence of new, well-tolerated VMAT2 inhibitor drugs is another factor significantly driving the growth of this market. VMAT2 inhibitors such as valbenazine and deutetrabenazine have shown greater safety, tolerability, and convenience relative to older therapies like tetrabenazine. Furthermore, regulatory approvals for broader indications and ongoing research and development are expanding the potential therapeutic applications. Moreover, the market expansion is supported by the growing favorable policies and strong commercialization from the leading pharmaceutical companies that are enhancing patient accessibility and market penetration.
 

VMAT2 inhibitors are a class of drugs that help in reducing the secretion of monoamines such as dopamine, serotonin, and norepinephrine by blocking their entry into synaptic vesicles. These drugs are majorly used to manage hyperkinetic movement disorders, such as Tardive Dyskinesia and chorea associated with Huntington’s Disease. They work by reducing excessive dopamine activity in the brain, which facilitates involuntary movements and motor dysfunction.
 

VMAT2 Inhibitors Market Trends

• The increasing prevalence of TD and Huntington's disease is one of the key trends propelling the growth of the market.
   
• As these diseases are the primary approved indications for VMAT2-targeting therapies such as valbenazine, deutetrabenazine, and tetrabenazine, the growing prevalence of these diseases contributes to the growth of this market.
   
• TD refers to an involuntary movement disorder usually associated with long-term use of antipsychotic medications, particularly dopamine receptor antagonists. The increasing use of antipsychotics for the management of diseases such as schizophrenia, bipolar disorder, and major depressive disorder results in high risk of TD.
   
• For instance, as per an article published by the National Institutes of Health (NIH), the estimated prevalence of TD ranges between 20% to 50% among patients using antipsychotics, with the reported incidence ranging from less than 1% to 42%, depending on the type and duration of antipsychotic exposure.
• Such increasing figures demonstrate a substantial at-risk population, of which many remain undiagnosed or undertreated.
   
• The increasing efforts and initiatives to improve clinical awareness of the diseases are expected to contribute to the growing adoption of VMAT2 inhibitors.
   
• On the other hand, Huntington's disease, which is a rare but fatal neurodegenerative disease, also drives the demand for VMAT2 inhibitors. Though it is less prevalent than TD, its prevalence varies across different regions.
   
• Thus, as the diagnosis rate and the awareness of these diseases increase, eventually the demand for safe, effective, and targeted treatment options like VMAT2 inhibitors is also expected to grow.
   
• Along with the increasing prevalence of TD and HD, the supportive regulatory frameworks, and growing investments for developing novel drugs are further anticipated to remain significant trends driving the growth of the global market for coming years.
   

Trump Administration Tariffs

• The Trump administration tariffs might significantly influence the growth of VMAT2 inhibitors market.
   
• The planned pharmaceutical tariffs, which President Trump announced will be implemented "very shortly", may impact active pharmaceutical ingredients imported from countries like China, which is one of the global suppliers for VMAT2 inhibitors such as valbenazine, deutetrabenazine, and tetrabenazine.
   
• If implemented, these tariffs could potentially result in higher manufacturing costs for VMAT2 inhibitors, as pharmaceutical companies might need to absorb these costs due to price constraints from regulations like the Inflation Reduction Act, as indicated by industry leaders.
   
• This potential cost pressure may limit access to treatment in price-sensitive markets, as pharmaceutical companies could face challenges maintaining affordability for patients and healthcare systems while managing increased production expenses.
   
• Supply chain disruptions resulting from increased trade restrictions might lead to delayed production and distribution, potentially forcing pharmaceutical companies to seek alternative suppliers or establish domestic production facilities.
   
• In the long run, these tariffs might potentially slow the growth of the market by creating regulatory uncertainty, potentially discouraging some investments, and impacting the innovation and accessibility of these critical treatments for conditions like Huntington's disease and tardive dyskinesia.
   

VMAT2 Inhibitors Market Analysis

In 2021, the global market was valued at USD 4 billion. Further, the market experienced slight growth and was valued at USD 4.3 billion in 2022 and USD 4.6 billion in 2023.
 

Based on the drug, the market is segmented valbenazine, deutetrabenazine, and tetrabenazine. The valbenazine segment dominated the market and was valued at USD 2.4 billion in 2024.
 

• Valbenazine is the first approved Tardive dyskinesia therapeutics, marketed as Ingrezza, thus giving it a critical first-mover advantage. The early market entry of this drug allowed it to establish brand-level recognition, build confidence among healthcare professionals leading to high prescription volume, and capture a substantial share of the TD treatment market.
   
• Additionally, the favorable safety and proven efficacy of this drug further contribute to the growing adoption of valbenazine.
   
• Furthermore, its convenience in dosing regimen offers improved patient adherence compared to traditional therapies.
   
• Moreover, valbenazine is approved for broader indications including TD and HD, thus increasing its demand and solidifying its dominant position in the market.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on the application, the VMAT2 inhibitors market is divided into Tardive dyskinesia and Huntington's disease. The Tardive dyskinesia segment held the highest market share of 74.9% in 2024.
 

• One of the major factors for the growth of this segment is the increasing prevalence of TD, particularly among patients on long-term treatment with antipsychotics, commonly used to treat psychiatric disorders such as schizophrenia, bipolar disorder, and major depression.
   
• Thus, the increasing patient base contributes to the growing demand for effective treatment options like VMAT2 inhibitors.
   
• Further, the approval and commercialization of drugs specially approved for treating TD such as valbenazine and deutetrabenazine have provided safe and effective treatment options, thereby driving diagnosis and treatment rates.
   
• Moreover, the growing awareness initiatives and programs further boost the growth of this segment, allowing better screening practices and management of the disease.
   
• For instance, the National Alliance on Mental Illness (NAMI) recognizes 4th May to 10th May as Tardive Dyskinesia (TD) Awareness Week to reduce the social stigma and empower the patients affected with the condition. Such awareness initiatives further fuel the market by increasing diagnosis rates and the adoption of VMAT2 inhibitors for treating TD.
   

Based on the type, the VMAT2 inhibitors market is classified as branded and generic. The branded segment is expected to grow at a significant CAGR of 9.3% during the forecast period.
 

• These drugs are backed by extensive clinical trials data, trust, and confidence among healthcare providers and well-established commercialization strategies, thus supporting the growth of this segment.
   
• The limited availability of generic alternatives of these VMAT2 inhibitor drugs further drives the high adoption of the branded drugs for treating TD and HD.
   
• Furthermore, these therapies are often supported with strong post-market surveillance and better reimbursement policies, thereby propelling the growth of branded drugs in the market.
   

Based on the distribution channel, the VMAT2 inhibitors market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment accounted for USD 2.4 billion in 2024 and is expected to reach USD 5.9 billion by 2034.
 

• Patients with severe TD and HD are often monitored in hospital settings due to the critical nature of VMAT2 inhibitor therapies. Hospitals provide better infrastructure and comprehensive patient evaluation, thus making hospital pharmacies a preferred option for dispensing these medications.
   
• The availability and accessibility of a wide range of products in hospital pharmacies further reinforce their market share in the global market.
   
• Moreover, the increased diagnosis rates in healthcare settings such as hospitals or specialty centers are further boosting the distribution of VMAT2 inhibitors through these channels.
   

The North America VMAT2 inhibitors market held the largest market share of 39.5% in 2024 in the global market, and it is anticipated to grow at 9.4% CAGR over the forecast period.
 

The U.S. market was valued at USD 1.8 billion in 2024. In 2021, the market was valued at USD 1.5 billion and further witnessed growth from USD 1.6 billion in 2022 to USD 1.7 billion in 2023.
 

• As per the National Organization of Tardive Dyskinesia, 750,000 individuals in the U.S. are affected with TD. This substantial patient population requiring long-term symptom management highlights the growing demand for VMAT2 inhibitors in the country.
   
• Further, the greater access to psychiatric care and advanced diagnostic capabilities drives the growth of the U.S. market.
   
• Moreover, the improved healthcare system and favorable reimbursement policies significantly contribute to the increased availability and accessibility of these drugs in the U.S.
   

The Germany VMAT2 inhibitors market is anticipated to experience robust growth in Europe market.
 

• As per the Statistisches Bundesamt, the population of retirement age (67 years or over) in Germany is expected to rise by approximately 4 million, reaching at least 20 million by the mid-2030s. This aging population is more prone to conditions like Tardive Dyskinesia (TD) and Huntington's disease, continuously driving the demand for VMAT2 inhibitors.
   
• Additionally, Germany has a strong presence of pharmaceutical companies driving the innovation and development of novel VMAT2 inhibitor therapies, leading to early adoption of advanced therapies, and further supporting market penetration.
   

India VMAT2 inhibitors market is expected to witness substantial growth in the Asia Pacific market during the analysis period.
 

• The healthcare system in India has seen significant improvements, especially in urban areas, which has resulted in better diagnosis and treatment of various diseases including TD and HD.
   
• Furthermore, as India is a major producer of generic drugs, the availability of generic drugs by players like Lupin has further boosted the growth of the market in India.
   

The Brazil VMAT2 inhibitors industry is poised to showcase robust growth in Latin America market.
 

• The rising prevalence of neurological and psychiatric disorders, particularly Tardive Dyskinesia and Huntington's disease, is a primary factor driving the growth of this market.
   
• Additionally, the growing awareness of diseases and availability of treatment options further foster the growth of this market.
   
• Moreover, the inclusion of VMAT2 inhibitor therapies in public health programs or reimbursement schemes is expected to surge the growth of the Brazil market in coming years.
   

The South Africa VMAT2 inhibitors market is projected to grow within Middle East and Africa during the analysis period.
 

• As per the research article by Rare Disorder Advisor, the prevalence of HD was estimated to be 0.25 per 100,000 in Africa, 0.41 per 100,000 in East Asia, and 2.39 per 100,000 across combined Middle Eastern and East Asian populations.
   
• This leads to a rise in the number of individuals diagnosed requiring effective treatment.
   
• Moreover, enhanced access to specialist care, diagnostic tools, and a growing number of neurologists further support the growth of the South Africa market.
   

VMAT2 Inhibitors Market Share

The market is competitive due to the presence of both branded and generic manufacturers. The top 3 players like Neurocrine Biosciences, Teva Pharmaceutical Industries, and Bausch Health Companies account for approximately 60 - 80% of market share by offering branded products like Ingrezza and Austedo, benefiting from established brand loyalty and robust clinical data. However, generic manufacturers such as Lupin are increasing competition by providing cost-effective alternatives, which are likely to drive overall market expansion in the long term.
 

The emerging competition from generic drugs in the VMAT2 inhibitors space is expected to shift the market dynamics, particularly in price-sensitive regions. Companies that can innovate and offer both efficacy and affordability will secure a larger market share.
 

VMAT2 Inhibitors Market Companies

Major players operating in the VMAT2 inhibitors industry are:

• Actavis Labs
• APOTEX
• Bausch Health Companies
• BionPharma
• Dr. Reddy's Laboratories
• H. Lundbeck
• Intas Pharmaceuticals Ltd
• Lupin
• Mylan
• Neurocrine Biosciences
• Teva Pharmaceutical Industries
• Upsher-Smith Laboratories
   
• Neurocrine Biosciences demonstrates strong leadership in the market through continuous innovation, exemplified by the initiation of a Phase 1 trial for NBI-1140675, a next-generation, selective oral VMAT2 inhibitor. This pipeline advancement reinforces the company's commitment to expanding treatment options for neurological and neuropsychiatric conditions, positioning it at the forefront of VMAT2-targeted therapeutic development.
   
• Lupin Limited strengthens its position in the VMAT2 inhibitors market with the FDA approval of its generic valbenazine capsules (40 mg and 80 mg), offering a cost-effective alternative to Neurocrine Biosciences' Ingrezza. This approval enhanced Lupin's portfolio, expanding access to effective treatments for Tardive Dyskinesia while addressing growing demand for affordable, high-quality generic options in the neurological therapeutics space.
   

VMAT2 Inhibitors Industry News

• In August 2023, Neurocrine Biosciences announced that the U.S. Food and Drug Administration (FDA) has approved INGREZZA (valbenazine) capsules for the treatment of adults with chorea associated with Huntington's disease (HD). This regulatory milestone expanded Ingrezza's therapeutic scope beyond Tardive Dyskinesia, further strengthening the company's market position in the VMAT2 inhibitor segment and opening new revenue streams.
   
• In February 2023, Teva Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) had approved AUSTEDO XR (deutetrabenazine) extended-release tablets, a once-daily formulation for the treatment of Tardive Dyskinesia (TD) and chorea associated with Huntington's disease (HD) in adults. This approval enhanced patient convenience and adherence, allowing Teva to strengthen its competitive position and broaden its market reach within the VMAT2 inhibitor class.
   
• In June 2022, Mitsubishi Tanabe Pharma Corporation announced the launch of DYSVAL capsules 40mg (valbenazine) in Japan for the treatment of Tardive Dyskinesia, following its inclusion in the NHI drug price listing on May 25, 2022. This launch marked a significant step in expanding MTPC's neurology portfolio and allowed the company to tap into the growing demand for innovative TD treatments in the Japanese market.
   

The VMAT2 inhibitors market research report includes in-depth coverage of the industry with estimates and forecasts in terms of revenue in USD Million from 2021 - 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Drug

• Valbenazine
• Deutetrabenazine
• Tetrabenazine

Market, By Application

• Tardive dyskinesia (TD)
• Huntington's disease

Market, By Type

• Branded
• Generic

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE